☰

Tu Xu, Ph.D. - Publications

Affiliations: 
2013 Mathematics, Statistics, and Computer Science University of Illinois at Chicago, Chicago, IL, United States 
Area:
Biostatistics, Epidemiology
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801600. PMID 30892988 DOI: 10.1200/Jco.18.01600  0.347
2018 DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. PMID 30361262 DOI: 10.1182/Blood-2018-08-868752  0.368
2018 Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, et al. Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10. PMID 29899021 DOI: 10.1126/Scitranslmed.Aaq1240  0.323
2018 DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology. PMID 29339097 DOI: 10.1016/S1470-2045(18)30010-X  0.35
2018 Wei A, Strickland SA, Hou J, Fiedler W, Lin TL, Walter RB, Enjeti AK, Hong W, Chyla B, Popovic R, Fakouhi K, Xu T, Hayslip J, Roboz GJ. Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy Blood. 132: 284-284. DOI: 10.1182/Blood-2018-99-118729  0.399
2018 Pollyea DA, Pratz KW, Jonas BA, Letai A, Pullarkat VA, Wei A, Konopleva MY, Recher C, Frankfurt O, Rizzieri D, Xu T, Dail M, Chyla B, Potluri J, DiNardo CD. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy Blood. 132: 285-285. DOI: 10.1182/Blood-2018-99-117179  0.393
2018 DiNardo CD, Pratz K, Potluri J, Pullarkat V, Jonas BA, Wei AH, Becker PS, Frankfurt O, Xu T, Hong W, Chyla B, Pollyea DA, Letai A. Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 18: S201. DOI: 10.1016/J.Clml.2018.07.050  0.313
2017 Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. PMID 29018077 DOI: 10.1182/Blood-2017-06-788786  0.362
2017 Bueno O, Xu T, Cordero J, Morris L, Ross J, Freise K, Munasinghe W, Leverson J, Mudd S, Verdugo M. Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 35: TPS8056-TPS8056. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8056  0.376
2017 Potluri J, Xu T, Hong W, Mabry MH. Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps7069  0.339
2017 Wei A, Strickland SA, Roboz GJ, Hou J, Fiedler W, Lin TL, Walter RB, Enjeti A, Chyla B, Popovic R, Fakouhi K, Shah P, Dunbar M, Xu T, Mabry M, et al. Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes Blood. 130: 890-890. DOI: 10.1182/Blood.V130.Suppl_1.890.890  0.386
2017 DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, Kantarjian HM, Pigneux A, Recher C, Seymour JF, Dunbar M, Xu T, Mabry M, Potluri J, Pratz K, et al. Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Blood. 130: 2628-2628. DOI: 10.1182/Blood.V130.Suppl_1.2628.2628  0.374
2017 Roberts AW, Xu T, Jia J, Agarwal S, Salem AH, Bellin RJ, Lam LT, Leverson JD. Do Statins Enhance the Anti-Cancer Activity of Venetoclax? Blood. 130: 1737-1737. DOI: 10.1182/Blood.V130.Suppl_1.1737.1737  0.373
2016 Wang S, Pan Y, Zhang R, Xu T, Wu W, Zhang R, Wang C, Huang H, Calin CA, Yang H, Claret FX. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5. Oncogene. PMID 27157611 DOI: 10.1038/onc.2016.147  0.334
2016 Kumar S, Vij R, Kaufman JL, Mikhael J, Facon T, Pegourie B, Benboubker L, Gasparetto C, Amiot M, Moreau P, Alzate S, Ross J, Dunbar M, Xu T, Agarwal S, et al. Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study Blood. 128: 488-488. DOI: 10.1182/Blood.V128.22.488.488  0.328
Show low-probability matches.